Skip to main content
SCI logo

SCI — Investor Relations & Filings

Ticker · 4119 ISIN · TW0004119003 TW Manufacturing
Open in API
Filings indexed 1,697 across all filing types
Latest filing 2021-06-09 Regulatory Filings
Country TW Taiwan
Listing TW 4119

About SCI

www.sci-pharmtech.com.tw

SCI Pharmtech, Inc. specializes in the research, development, manufacturing, and marketing of Active Pharmaceutical Ingredients (APIs), pharmaceutical intermediates, and specialty chemicals. Established in 1987 and originally founded by the Swiss Siegfried Group, the company provides high-quality chemical solutions and custom manufacturing services to leading global pharmaceutical corporations across Europe, North America, and Japan. Its core operations encompass advanced chemical synthesis, process optimization, and large-scale production within GMP-compliant facilities. With a robust R&D infrastructure including specialized laboratories and pilot plants, the company delivers technical excellence in complex chemical processing. SCI Pharmtech maintains a strong focus on quality assurance and international regulatory compliance, positioning itself as a reliable partner for the global healthcare and life sciences sectors.

Recent filings

Filing Released Lang Actions
110年5月背書保證與資金貸與
Regulatory Filings Classification · 95% confidence The document is a brief financial disclosure from a listed company, providing information about loan balances and guarantee endorsements for the current and previous months, with zero amounts reported. It is a short, factual update without detailed financial statements or analysis. The content does not correspond to a full financial report like an Annual Report or Interim Report, nor does it announce a meeting or voting results. It is a regulatory disclosure of financial status related to guarantees and loans, fitting best under general regulatory announcements that do not fit other categories.
2021-06-09 Chinese
110年5月營業收入
Regulatory Filings Classification · 95% confidence The document is a revenue summary report provided by a listed company, showing monthly and cumulative net operating revenue figures with percentage changes and explanations. It is a brief financial data disclosure, not a full financial report or detailed analysis. The document length is only 800 characters, and it mainly provides summarized financial figures and notes on revenue changes due to operational impacts (fire damage). There is no indication of a full annual or interim report, audit report, or earnings release. It is a regulatory disclosure of financial data, typical of a Regulatory Filing (RNS) category, as it does not meet the criteria for a full Interim/Quarterly Report (IR) or Annual Report (10-K).
2021-06-09 Chinese
本公司依金管會指示停止召開原訂股東常會
Regulatory Filings Classification · 95% confidence The document is a short announcement (580 characters) from a company (4119 旭富) stating that it is stopping the originally scheduled Annual General Meeting (AGM) due to regulatory instructions related to pandemic measures. It specifies the original AGM date and mentions rescheduling within a certain period. There is no detailed report, financial data, or presentation content. The document is an announcement about the postponement of the AGM, not the AGM materials themselves or any financial report. Therefore, it fits best under Regulatory Filings (RNS) as a general regulatory announcement about meeting schedule changes.
2021-05-21 Chinese
依據臺證上一字第1091806531號函辦理及補充說明。
Regulatory Filings Classification · 95% confidence The document is a short disclosure from a listed company (4119 旭富) providing financial information as of April 2021 (110 year in ROC calendar). It includes specific financial data such as cash and cash equivalents, financial assets measured at fair value, short-term borrowings, and other accounting items. The document references a regulatory letter (臺證上一字第1091806531號函) and is a compliance filing. The length is only 819 characters, and it is a factual announcement of financial data rather than a full financial report or detailed analysis. It does not contain comprehensive financial statements or management discussion. It is not an earnings release or annual/interim report but a regulatory disclosure of financial status. Given the nature and length, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements and compliance documents that do not fit other specific categories.
2021-05-19 Chinese
110年04月董事會成員及持股
Director's Dealing Classification · 95% confidence The document is a detailed tabulation of shareholdings by insiders and related parties of the company 旭富製藥科技股份有限公司. It lists positions such as Chairman, Vice Chairman, Directors, Independent Directors, General Manager, Deputy General Managers, Managers, and other key personnel along with their shareholdings, pledged shares, and related information. The document does not contain financial statements, earnings data, or management discussion of financial results. It is focused on insider shareholdings and related disclosures. This type of document corresponds to a Director's Dealing report, which reports personal share transactions or holdings by company directors and executives. The document length is 3148 characters, which is consistent with a detailed insider shareholding disclosure rather than a full financial report or announcement. Therefore, the appropriate classification is Director's Dealing (DIRS).
2021-05-12 Chinese
110年04月內部人持股異動(事後)
Director's Dealing Classification · 95% confidence The document consists of detailed tables listing shareholdings and stock ownership information of company insiders, including directors, managers, and their related parties. It includes data on shares held, increases, decreases, and other stock-related details. There is no indication of financial statements, earnings data, legal proceedings, or meeting materials. The content is focused on insider shareholdings and transactions. This matches the definition of Director's Dealing (DIRS), which reports personal share transactions by company directors and executives (insider trades). The document length is sufficient and contains substantive data, not just an announcement or certification. Therefore, the appropriate classification is DIRS.
2021-05-12 Chinese

Browse filings by year

14 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.